FDA to Bio-Makers: Tell Us About Your Oopsy-Daisies in Production
Published Date: 2/25/2026
Notice
Summary
The FDA wants to hear from companies that make biological products and human tissues about how they report mistakes during manufacturing. They’re asking for feedback on updating the forms and rules to keep things clear and safe. If you’re involved in making these products, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just a chance to help improve the process!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Mandatory 45‑Day Deviation Reporting
If you manufacture biological products, blood products, or regulated human cells and tissues, you must report product deviations using Form FDA 3486 as soon as possible but no later than 45 calendar days after learning of a reportable event. FDA estimates an average 2 hours to complete each deviation report; there are 17,818 total annual responses and a total estimated 43,246.25 annual burden hours (an increase of 13,602.95 hours and 2,383 responses based on FY2024 data).
Addendum and Partial Electronic Filing Rules
CBER offers an electronic report option and a web‑based addendum (Form FDA 3486A) for reports that may lead to a recall; FDA estimates 5% of CBER reports (about 825 annual addendum responses) and 15 minutes to complete each addendum. CDER currently does not accept electronic filings, so submissions to CDER must be made by non‑electronic methods.
Public Comment Opportunity by April 27, 2026
FDA is asking companies and stakeholders involved in biological product and HCT/P manufacturing to submit comments on the proposed information collection by April 27, 2026, via regulations.gov or by mail. The notice explains how to submit confidential information and that comments filed electronically will be posted publicly.
No Capital or O&M Costs Claimed
FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection for respondents. The burden estimate covers only reporting time, not equipment or other capital expenses.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03772 — Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds
The FDA wants feedback on how medicated animal feed makers keep their records to make sure everything’s safe and up to date. This affects companies that produce medicated feeds, and they have until April 27, 2026, to share their thoughts. No big money changes yet, just a chance to improve how info is collected and stored.
Next: 2026-03774 — Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
The FDA just got the green light from the Office of Management and Budget to keep collecting important info from food and drug businesses. This means rules about food safety, facility registration, and tracking shipments stay in place through 2028, helping protect everyone’s health without extra costs or delays. If you’re involved in food or drug industries, keep an eye on these updates to stay on track!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in